Welcome to our dedicated page for BIONTECH SEC filings (Ticker: BNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioNTech SE filings document the disclosures of a foreign private issuer that reports to the SEC primarily through Form 6-K current reports and annual reports on Form 20-F. The records cover interim condensed consolidated financial statements, operating and financial reviews, corporate updates, and exhibit filings related to press releases and investor presentations.
BioNTech’s filings also describe ADS-related capital actions, including repurchase program disclosures for American Depositary Shares representing ordinary shares. Other recurring subjects include annual general meeting invitations and shareholder voting mechanics, governance matters, clinical and regulatory updates for oncology programs, COVID-19 vaccine activity, collaboration-related pipeline information, and material-event disclosures affecting capital allocation and corporate strategy.
BioNTech SE submitted a report describing a strategic business update delivered at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. On January 13, 2026, the company outlined its focus areas for 2026 and provided an overview of expected near- to longer-term milestones. The related presentation is made available as Exhibit 99.1 to this report.
BioNTech SE is using a 2026 strategic update to highlight its shift toward becoming a multi-product oncology company while relying on its COVID-19 franchise and strong balance sheet. The company expects seven late-stage oncology data readouts in 2026 and plans to have 15 Phase 3 clinical trials ongoing by year-end, across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies. By 2030+, BioNTech anticipates at least 17 late-stage or pivotal data readouts that could support multiple product launches in major tumors such as lung, breast, gynecologic and head and neck cancers.
Financially, BioNTech reported approximately €17.2 billion in cash, cash equivalents and security investments as of December 31, 2025 and in November 2025 raised its 2025 revenue guidance to €2.6–2.8 billion while lowering expense guidance ranges. For 2026, it anticipates a modest decline in Comirnaty revenues and does not expect to recognize revenues from oncology product sales, while revenues from its Bristol Myers Squibb collaboration are expected to be broadly in line with 2025.
BioNTech SE has effectively completed its exchange offer for CureVac N.V. shares. As of the expiration of the subsequent offering period at 12:01 a.m. New York City time on December 18, 2025, a total of 195,341,219 CureVac shares, representing approximately 86.75% of CureVac’s issued and outstanding capital, were validly tendered.
BioNTech expects to promptly pay for all CureVac shares tendered in the offer and then carry out a post-offer reorganization. After this reorganization, CureVac will no longer be publicly traded, its shares will be delisted from Nasdaq, and the shares will be deregistered under the Exchange Act, ending CureVac’s ongoing SEC reporting obligations.
BioNTech SE has effectively completed its exchange offer for CureVac N.V. shares. As of the expiration of the subsequent offering period at 12:01 a.m. New York City time on December 18, 2025, a total of 195,341,219 CureVac shares, representing approximately 86.75% of CureVac’s issued and outstanding capital, were validly tendered.
BioNTech expects to promptly pay for all CureVac shares tendered in the offer and then carry out a post-offer reorganization. After this reorganization, CureVac will no longer be publicly traded, its shares will be delisted from Nasdaq, and the shares will be deregistered under the Exchange Act, ending CureVac’s ongoing SEC reporting obligations.
BioNTech SE reports that it has completed its exchange offer for all outstanding shares of CureVac N.V., following the expiration of the subsequent offering period. This means CureVac is now being acquired by BioNTech through a share-exchange structure rather than a cash-only deal. The company states that this step closes the acquisition process and is intended to strengthen BioNTech’s position in the mRNA field. The press release describing the transaction is included as an exhibit and this report is incorporated by reference into BioNTech’s existing Form F-4 registration statement.
BioNTech SE submitted a Form 6-K reporting that it issued a press release on November 26, 2025 about its exchange offer for all outstanding shares of CureVac N.V.. The press release announces the results of CureVac’s extraordinary general meeting and the calculation of the exchange ratio for the offer.
The filing states that this Form 6-K is incorporated by reference into BioNTech’s Form F-4 registration statement. The attached press release, filed as Exhibit 99.1, highlights progress on the exchange offer and notes a December 3, 2025 at 9:00 a.m. Eastern Time expiration for the offer.
BioNTech SE issued a supplement to its prospectus for the public offer to CureVac (CVAC) shareholders, covering an exchange of 15,061,575 newly registered ADSs of BioNTech for all CureVac ordinary shares. The supplement is approved by BaFin, with withdrawal rights exercisable until November 14, 2025.
BioNTech updated financials: nine‑month revenues €1,962.5 million, net loss €831.1 million, and cash and cash equivalents €10,092.9 million. Total cash, cash equivalents and security investments were €16,704.9 million as of September 30, 2025. Q3 results reflect €613.0 million of out‑licensing revenue from the BMS collaboration (part of a $1.5 billion upfront received), and other operating expenses linked to GSK/CureVac settlement arrangements of €678.5 million.
For 2025, management’s forecast assumes revenues €2.6–€2.8 billion, R&D €2.0–€2.2 billion, and SG&A €550–€650 million, and confirms an expected net loss for 2025. The company notes seasonal COVID‑19 vaccine demand, narrower FDA approval scope for its LP.8.1‑adapted vaccine, and ongoing late‑stage oncology development including pumitamig (BNT327).
BioNTech SE issued a supplement to its prospectus for the public offer to CureVac (CVAC) shareholders, covering an exchange of 15,061,575 newly registered ADSs of BioNTech for all CureVac ordinary shares. The supplement is approved by BaFin, with withdrawal rights exercisable until November 14, 2025.
BioNTech updated financials: nine‑month revenues €1,962.5 million, net loss €831.1 million, and cash and cash equivalents €10,092.9 million. Total cash, cash equivalents and security investments were €16,704.9 million as of September 30, 2025. Q3 results reflect €613.0 million of out‑licensing revenue from the BMS collaboration (part of a $1.5 billion upfront received), and other operating expenses linked to GSK/CureVac settlement arrangements of €678.5 million.
For 2025, management’s forecast assumes revenues €2.6–€2.8 billion, R&D €2.0–€2.2 billion, and SG&A €550–€650 million, and confirms an expected net loss for 2025. The company notes seasonal COVID‑19 vaccine demand, narrower FDA approval scope for its LP.8.1‑adapted vaccine, and ongoing late‑stage oncology development including pumitamig (BNT327).
BioNTech SE issued an Update to its UK Exemption Document for the public offer to CureVac N.V. shareholders, confirming the exchange of 15,061,575 newly registered BioNTech ADSs for all CureVac ordinary shares. The Update incorporates Q3 2025 financials and recent developments.
For the nine months ended September 30, 2025, BioNTech reported revenues of €1,962.5 million, driven by €613.0 million of out‑licensing revenue from its BMS partnership and €1,139.6 million from COVID‑19 vaccine collaborations. Operating loss was €1,082.1 million and net loss €831.1 million, reflecting €678.5 million in expenses related to the GSK/CureVac Settlement Arrangements. Cash, cash equivalents and securities totaled €16,704.9 million as of September 30, 2025.
The company reaffirmed its 2025 outlook: revenues of €2.6–€2.8 billion, research and development expenses of €2.0–€2.2 billion, sales, general and administrative expenses of €550–€650 million, and that it does not expect to report positive net income for 2025. Clinical updates include progress of pumitamig (BNT327) under the BMS collaboration and ongoing oncology programs.
BioNTech SE issued an Update to its UK Exemption Document for the public offer to CureVac N.V. shareholders, confirming the exchange of 15,061,575 newly registered BioNTech ADSs for all CureVac ordinary shares. The Update incorporates Q3 2025 financials and recent developments.
For the nine months ended September 30, 2025, BioNTech reported revenues of €1,962.5 million, driven by €613.0 million of out‑licensing revenue from its BMS partnership and €1,139.6 million from COVID‑19 vaccine collaborations. Operating loss was €1,082.1 million and net loss €831.1 million, reflecting €678.5 million in expenses related to the GSK/CureVac Settlement Arrangements. Cash, cash equivalents and securities totaled €16,704.9 million as of September 30, 2025.
The company reaffirmed its 2025 outlook: revenues of €2.6–€2.8 billion, research and development expenses of €2.0–€2.2 billion, sales, general and administrative expenses of €550–€650 million, and that it does not expect to report positive net income for 2025. Clinical updates include progress of pumitamig (BNT327) under the BMS collaboration and ongoing oncology programs.
BioNTech SE filed a Form 6‑K noting it hosted an edition of its Innovation Series R&D Day on November 11, 2025, providing an overview of strategy and clinical progress across its pipeline.
The related presentation is attached as Exhibit 99.1. The filing is signed by Chief Financial Officer Ramon Zapata‑Gomez and Chief Operating Officer Dr. Sierk Poetting.
BioNTech SE submitted a Form 6‑K as a foreign private issuer to provide investors with a development update and its latest financial information. On November 3, 2025, the company reported its financial results for the three and nine months ended September 30, 2025, and prepared interim condensed consolidated financial statements for that period. These financial statements, along with an operating and financial review and prospects section, are included as Exhibit 99.1 to the report and are deemed filed under the Securities Exchange Act. The filing is signed on behalf of BioNTech SE by its Chief Financial Officer and Chief Operating Officer.
BioNTech SE furnished a Form 6‑K announcing its third quarter 2025 financial results and corporate update. The company scheduled a conference call for 8:00 am EST on November 3, 2025 to discuss the results. A press release and presentation were provided as Exhibits 99.1 and 99.2 and are incorporated by reference. The materials are designated as furnished and not deemed filed under the Exchange Act unless specifically referenced in a future filing.